A randomized, double-blind, placebo-controlled, multi-center study toevaluate the efficacy, safety, tolerability, pharmacokineti

A randomized, double-blind, placebo-controlled, multi-center study toevaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered GLPG3667 once daily for 24 weeks in adult subjects with dermatomyositis

Abierta

Código protocolo: GLPG3667-CL-214
Código EudraCT: _
Grupo de investigación: Enfermedades Sistémicas
Servicio: Medicina Interna
Investigador/a principal: Selva O'Callaghan, Albert
Patología: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Fase: Fase II